Without guidance, which GW has point blank refused to give the, dose sales are the only measure we have apart from waiting for the 6 mth reports. Many companies give the market regular 1/4 sales numbers.
Some even give trading results for the Xmas period and on a store for store basis so instos can analysis the real growth as opposed to opening new stores (investment growth).
I'd love to see the like for like dose sales over say the top 50 hospitals in the US - this is where we can get an indication of future growth as opposed to opening new centres which although is important, can cover a zero growth scenario.
I'm not suggesting there is zero growth at all, but clarity on the numbers would attract insto support.
SRX Price at posting:
$19.07 Sentiment: Hold Disclosure: Held
